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Background
Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose 
regimen, may be an option for the extended treatment of venous thromboembolism.
Methods
In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg 
and 5 mg, twice daily) with placebo in patients with venous thromboembolism who 
had completed 6 to 12 months of anticoagulation therapy and for whom there was 
clinical equipoise regarding the continuation or cessation of anticoagulation ther-
apy. The study drugs were administered for 12 months.
Results
A total of 2486 patients underwent randomization, of whom 2482 were included in 
the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism 
or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) 
who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who 
were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% con-
fidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiv-
ing 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) 
(P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the pla-
cebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban 
group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo 
group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. 
The rate of death from any cause was 1.7% in the placebo group, as compared with 
0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.
Conclusions
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a 
thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thrombo-
embolism without increasing the rate of major bleeding. (Funded by Bristol-Myers 
Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.)
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Venous thromboembolism, which in-cludes deep-vein thrombosis and pulmo-nary embolism, is the third most common 
cause of vascular disease–related deaths.1 The 
mainstay of treatment is anticoagulation, and 
guidelines recommend therapy for 3 months or 
longer.2,3 Decisions about extending treatment 
are challenging. Although warfarin is effective 
for the prevention of recurrent venous thrombo-
embolism, the inconvenience of laboratory mon-
itoring and the dietary restrictions, coupled with 
concerns about bleeding, often lead to a reluc-
tance to continue warfarin therapy beyond 6 to 
12 months. Attempts to reduce the risk of bleed-
ing by lowering the intensity of warfarin therapy 
have resulted in decreased efficacy without less 
bleeding.4,5
If warfarin is discontinued, the risk of recur-
rent venous thromboembolism is 6 to 10% per 
year in patients without reversible risk factors.6-9 
In addition, such patients are at increased risk 
for arterial thrombotic events, such as myocar-
dial infarction, stroke, and vascular death,1,10,11 
and the rate of these events may also be reduced 
with anticoagulation therapy.12
Apixaban is an oral factor Xa inhibitor that is 
administered in fixed doses without the need for 
laboratory monitoring. At a dose of 5 mg twice 
daily, apixaban has been shown to be effective for 
the prevention of stroke in patients with atrial 
fibrillation, and at a dose of 2.5 mg twice daily, 
the lowest dose evaluated in phase 2 studies, it 
has been shown to be effective for thrombopro-
phylaxis after major orthopedic surgery.13-15 In 
the Apixaban after the Initial Management of 
Pulmonary Embolism and Deep Vein Thrombo-
sis with First-Line Therapy–Extended Treatment 
(AMPLIFY-EXT) study, we compared the efficacy 
and safety of these two doses of apixaban with 
those of placebo in patients with venous throm-
boembolism who had completed 6 to 12 months 
of anticoagulation therapy and for whom treat-
ing physicians were uncertain about continuing 
therapy. Additional aims of the study were to de-
termine whether the lower dose of apixaban was 
effective and whether it was associated with less 
bleeding than the higher dose and to examine 
the effect of treatment on arterial thrombotic 
outcomes.
Me thods
Study Design and Oversight
We conducted a randomized, double-blind study 
comparing the efficacy and safety of two doses 
of apixaban with those of placebo for the extend-
ed treatment of venous thromboembolism. The 
trial was sponsored by Bristol-Myers Squibb and 
Pfizer. The steering committee, comprising both 
academic and sponsor authors, had final respon-
sibility for the design of the study, the develop-
ment of the protocol, the oversight of the study, 
the verification of the data, and the analyses. The 
protocol was approved by the institutional review 
board at each participating center and is avail-
able with the full text of this article at NEJM.org. 
Written informed consent was obtained from all 
the patients. The sponsors collected and main-
tained the data; the academic authors had access 
to the data at all times, through the sponsors. An 
independent committee, whose members were 
unaware of the study-group assignments, adjudi-
cated the qualifying initial diagnosis (deep-vein 
thrombosis or pulmonary embolism) and all sus-
pected outcomes. An independent data monitor-
ing committee periodically reviewed the study 
outcomes. All members of the steering commit-
tee contributed to the interpretation of the re-
sults, wrote and approved all versions of the 
manuscript and made the decision to submit it 
for publication, and vouch for the accuracy and 
completeness of the data and for the fidelity of 
this article to the study protocol.
Patients
Patients were eligible for inclusion in the study if 
they were 18 years of age or older; if they had 
objectively confirmed, symptomatic deep-vein 
thrombosis or pulmonary embolism (with or 
without deep-vein thrombosis); if they had been 
treated for 6 to 12 months with standard antico-
agulant therapy or had completed treatment with 
apixaban or enoxaparin and warfarin as partici-
pants in the AMPLIFY trial (ClinicalTrials.gov 
number, NCT00643201); if they had not had a 
symptomatic recurrence during prior anticoagu-
lant therapy; and if there was clinical equipoise 
about the continuation or cessation of anticoagu-
lant therapy.
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Patients were ineligible if they had a contra-
indication to continued anticoagulant therapy or 
if they required ongoing anticoagulant therapy, 
dual antiplatelet therapy, or aspirin at a dose 
higher than 165 mg daily. Additional ineligibility 
criteria included a hemoglobin level of less than 
9 mg per deciliter, a platelet count of less than 
100,000 per cubic millimeter, a serum creatinine 
level of more than 2.5 mg per deciliter (221 μmol 
per liter) or a calculated creatinine clearance of 
less than 25 ml per minute, an alanine amino-
transferase or aspartate aminotransferase level 
that was more than 2 times the upper limit of 
the normal range, or a total bilirubin level that 
was more than 1.5 times the upper limit of the 
normal range. The full list of exclusion criteria 
is provided in the protocol.
Randomization
Randomization was performed with the use of an 
interactive voice-response system and was strati-
fied according to the initial diagnosis (deep-vein 
thrombosis or pulmonary embolism) and par-
ticipation or no participation in the AMPLIFY 
trial. Patients were enrolled within approximate-
ly 7 days after they received the last dose of prior 
anticoagulant therapy and, if they were receiving 
a vitamin K antagonist, when the international 
normalized ratio was 2.0 or lower.
Patients were assigned, in a 1:1:1 ratio, to 
receive 2.5 mg of apixaban, 5 mg of apixaban, or 
placebo, all given twice daily. The intended dura-
tion of administration of the study drug was 12 
months. During the course of the trial, dual anti-
platelet therapy, aspirin at a dose higher than 
165 mg daily, and potent inhibitors of cytochrome 
P-450 3A4 and P-glycoprotein were prohibited.
Outcome Measures
The primary efficacy outcome was the composite 
of symptomatic recurrent venous thromboembo-
lism or death from any cause — an outcome con-
sistent with that recommended in regulatory 
guidelines for trials of extended treatment for 
venous thromboembolic diseases.16 Recurrent 
venous thromboembolism included fatal and 
nonfatal pulmonary embolism and deep-vein 
thrombosis. Death was classified as related to 
venous thromboembolism, related to cardiovas-
cular disease, due to bleeding, or due to other 
causes.
Symptomatic recurrent venous thromboembo-
lism or death related to venous thromboembo-
lism was a prespecified secondary efficacy out-
come. A report11 published after the trial began 
prompted the addition of another secondary out-
come before the database was locked and the data 
were unblinded — the composite of symptomatic 
recurrent venous thromboembolism, death relat-
ed to venous thromboembolism, myocardial in-
farction, stroke, or death related to cardiovascular 
disease. The criteria for the diagnosis and adjudi-
cation of efficacy outcomes and their components 
are described in the protocol and in the Supple-
mentary Appendix, available at NEJM.org.
The primary safety outcome was major bleed-
ing. The secondary safety outcome was the com-
posite of major or clinically relevant nonmajor 
bleeding. Major bleeding was defined as overt 
bleeding that was associated with a decrease in 
the hemoglobin level of 2 g per deciliter or more, 
led to transfusion of 2 or more units of red cells, 
occurred in a critical site, or contributed to 
death.6,7 Clinically relevant nonmajor bleeding 
was defined as overt bleeding that did not meet 
the criteria for major bleeding but that was as-
sociated with the need for medical intervention, 
unscheduled contact with a physician, interrup-
tion or discontinuation of the study drug, or 
discomfort or impairment of activities of daily 
living17 (further details are provided in the Sup-
plementary Appendix). Net clinical benefit was 
defined as a reduction in the composite of symp-
tomatic recurrent venous thromboembolism, 
death related to venous thromboembolism, myo-
cardial infarction, stroke, death related to car-
diovascular disease, or major bleeding.
Surveillance and Follow-up
Patients underwent assessment, either in the 
clinic or by telephone, monthly during the in-
tended treatment period and 30 days after the 
end of the 1-year intended study period. Patients 
were instructed to report to the study center if 
they had symptoms suggestive of recurrent ve-
nous thromboembolism or bleeding. Prespeci-
fied objective testing was required for patients in 
whom an outcome event was suspected.
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Statistical Analysis
The study was designed to test the hypothesis that 
each dose of apixaban would be superior to pla-
cebo with respect to the primary efficacy outcome. 
Assuming an estimated incidence in the placebo 
group of 6.8% at 12 months and a decrease in the 
primary outcome of 41% with active treatment as 
compared with placebo,18,19 we calculated that we 
would need to enroll 810 patients in each group 
for the study to have 90% power to show the su-
periority of apixaban over placebo, at a two-sided 
alpha level of 0.05, with the use of the Hochberg 
multiple-testing method.20
All efficacy analyses included data from the 
intention-to-treat population during the 12-month 
active study period. All safety analyses included 
data from patients during the time they were re-
ceiving treatment, which was defined as the time 
between administration of the first dose of a 
study drug and 48 hours after administration of 
the last dose.
For the primary efficacy analysis, in accor-
dance with agreements with regulatory authori-
ties, patients who were lost to follow-up were 
classified as having had a primary outcome event. 
For the analyses of the secondary outcomes and 
Table 1. Demographic and Clinical Characteristics of the Patients.*
Characteristic
Apixaban, 2.5 mg 
(N = 840)




Age — yr 56.6±15.3 56.4±15.6 57.1±15.2
Male sex — no. (%) 487 (58.0) 469 (57.7) 468 (56.5)
Weight
Mean — kg 85.7±19.8 85.7±19.1 84.7±18.6
Distribution — no. (%)
≤60 kg 58 (6.9) 59 (7.3) 48 (5.8)
>60 kg 780 (92.9) 751 (92.4) 778 (93.8)
Data missing 2 (0.2) 3 (0.4) 3 (0.4)
Creatinine clearance — no. (%)
≤30 ml/min 1 (0.1) 3 (0.4) 2 (0.2)
>30 to ≤50 ml/min 47 (5.6) 41 (5.0) 44 (5.3)
>50 to ≤80 ml/min 174 (20.7) 168 (20.7) 194 (23.4)
>80 ml/min 595 (70.8) 580 (71.3) 564 (68.0)
Data missing 23 (2.7) 21 (2.6) 25 (3.0)
Initial diagnosis — no. (%)
Deep-vein thrombosis 544 (64.8) 527 (64.8) 551 (66.5)
Pulmonary embolism 296 (35.2) 286 (35.2) 278 (33.5)
Clinical presentation of VTE at initial diagnosis — no. (%)
Unprovoked 783 (93.2) 737 (90.7) 755 (91.1)
Associated with transient or reversible risk factor 56 (6.7) 76 (9.3) 72 (8.7)
Risk factors for recurrent VTE — no. (%)†
Active cancer 15 (1.8) 9 (1.1) 18 (2.2)
Persistent or permanent immobilization 19 (2.3) 29 (3.6) 22 (2.7)
Previous deep-vein thrombosis or pulmonary embolism 99 (11.8) 118 (14.5) 99 (11.9)
Known prothrombotic genotype 32 (3.8) 26 (3.2) 36 (4.3)
Use of antiplatelet agents‡ 120 (14.3) 96 (11.8) 107 (13.0)
* Plus–minus values are means ±SD. There were no significant differences among the study groups in the baseline char-
acteristics listed here. VTE denotes venous thromboembolism.
† Patients could have multiple risk factors.
‡ Data on the use of antiplatelet agents were calculated in the safety population (840 patients in the 2.5-mg apixaban 
group, 811 in the 5-mg apixaban group, and 826 in the placebo group), rather than the intention-to-treat population.
The New England Journal of Medicine 
Downloaded from nejm.org on March 9, 2021. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Apixaban for Extended Treatment of Venous Thromboembolism
n engl j med 368;8 nejm.org february 21, 2013 703
for the safety analyses, patients who were lost to 
follow-up were classified as not having had an 
outcome event.
In the analyses of efficacy and safety, the 
proportions of outcome events in the two groups 
were compared with the use of the Cochran–
Mantel–Haenszel test, stratified according to the 
initial diagnosis (deep-vein thrombosis or pulmo-
nary embolism). The time-to-event curves were 




From May 2008 through July 2011, a total of 2486 
patients were enrolled at 328 sites in 28 coun-
tries. Two patients in the 2.5-mg apixaban group 
and 2 patients in the 5-mg apixaban group were 
excluded from all the analyses because verifiable 
source documentation was lacking for them. The 
characteristics of patients in the three study groups 
were similar at baseline (Table 1). Figure 1 shows 
the random assignment and follow-up of the pa-
tients.
Efficacy
During the 1-year active study period, a primary 
efficacy outcome event occurred in 96 of the 829 
patients who were receiving placebo (11.6%), 32 
of the 840 patients who were receiving 2.5 mg of 
apixaban (3.8%), and 34 of the 813 patients who 
were receiving 5 mg of apixaban (4.2%) (Table 2). 
A total of 19 patients in the placebo group (2.3%), 
13 patients in the 2.5-mg apixaban group (1.5%), 
and 20 patients in the 5-mg apixaban group 
(2.5%) were lost to follow-up and were counted 
as having had a primary outcome event. Both 
2486 Patients underwent randomization
842 Were assigned to receive
apixaban, 2.5 mg
829 Were assigned to receive
placebo
2 Were excluded
840 Were included in intention-
to-treat efficacy analysis
813 Were included in intention-
to-treat efficacy analysis
 815 Were assigned to receive
apixaban, 5 mg
2 Were excluded




65 Had adverse event
7 Withdrew consent
2 Were lost to follow-up
39 Had other reasons
829 Were included in intention-
to-treat efficacy analysis
840 Were included in the safety
analysis
811 Were included in the safety
analysis





58 Had adverse event
12 Withdrew consent
4 Were lost to follow-up




126 Had adverse event
6 Withdrew consent
8 Were lost to follow-up
39 Had other reasons
Figure 1. Randomization and Follow-up.
Two patients in the 2.5-mg apixaban group and two patients in the 5-mg apixaban group were excluded from all the analyses because 
verifiable source documentation was lacking.
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apixaban doses were superior to placebo with re-
spect to the primary outcome (difference between 
placebo and 2.5 mg of apixaban, 7.8 percentage 
points [95% confidence interval (CI), 5.5 to 10.3] 
and difference between placebo and 5 mg of 
apixaban, 7.4 percentage points [95% CI, 4.8 to 
10.0]; P<0.001 for both comparisons).
Symptomatic recurrent venous thromboembo-
lism or death related to venous thromboembo-
lism occurred in 73 patients (8.8%) who were re-
ceiving placebo, as compared with 14 patients 
(1.7%) who were receiving 2.5 mg of apixaban (a 
difference of 7.2 percentage points; 95% CI, 5.0 
to 9.3; P<0.001) and 14 patients (1.7%) who were 
receiving 5 mg of apixaban (a difference of 7.0 
percentage points; 95% CI, 4.9 to 9.1; P<0.001). 
The difference in the rate of this outcome with 
the 2.5-mg dose as compared with the 5-mg dose 
was −0.2 percentage points (95% CI, −1.4 to 1.0). 
Figure 2A shows the time course of symptomatic 
recurrent venous thromboembolism and death 
related to venous thromboembolism. Results of 
the analysis of the combined outcome of all 
thromboembolic events (symptomatic recurrent 
venous thromboembolism, death related to ve-
nous thromboembolism, myocardial infarction, 
stroke, or death related to cardiovascular dis-
ease) are shown in Table 2.
Bleeding
Major bleeding occurred in four patients (0.5%) 
who were receiving placebo, as compared with 
two patients (0.2%) who were receiving 2.5 mg of 
apixaban (a difference of 0.2 percentage points; 
95% CI, −0.3 to 0.8) and one patient (0.1%) who 
was receiving 5 mg of apixaban (a difference of 
0.4 percentage points; 95% CI, −0.2 to 0.9). The 
difference in the rate of major bleeding with the 
2.5-mg dose as compared with the 5-mg dose 
was 0.1 percentage points (95% CI, −0.3 to 0.5).
Clinically relevant nonmajor bleeding oc-
curred in 19 patients (2.3%) who were receiving 
placebo, as compared with 25 patients (3.0%) who 
were receiving 2.5 mg of apixaban (a difference 
of −0.7 percentage points; 95% CI, −2.2 to 0.9) 
and 34 patients (4.2%) who were receiving 5 mg 






5 mg  
(N = 813)
Placebo 
(N = 829) Relative Risk (95% CI)
Apixaban, 2.5 mg, 
vs. Placebo
Apixaban, 5 mg,  
vs. Placebo
Apixaban, 2.5 mg  
vs. 5 mg
number (percent)
Recurrent VTE or death from any cause 
— primary efficacy outcome†
32 (3.8) 34 (4.2) 96 (11.6) 0.33 (0.22–0.48) 0.36 (0.25–0.53) NA
Recurrent VTE or VTE-related death 14 (1.7) 14 (1.7) 73 (8.8) 0.19 (0.11–0.33) 0.20 (0.11–0.34) 0.97 (0.46–2.02)
Non–VTE-related cardiovascular death, 
myocardial infarction, or stroke
4 (0.5) 5 (0.6) 11 (1.3) 0.36 (0.11–1.12) 0.47(0.16–1.33) 0.77 (0.21–2.88)
Recurrent VTE, VTE-related death, myo-
cardial infarction, stroke, or cardio-
vascular disease–related death
18 (2.1) 19 (2.3) 83 (10.0) 0.21 (0.13–0.35) 0.23 (0.14–0.38) 0.92 (0.48–1.74)
Major bleeding 2 (0.2) 1 (0.1) 4 (0.5) 0.49 (0.09–2.64) 0.25 (0.03–2.24) 1.93 (0.18–21.25)
Clinically relevant nonmajor bleeding 25 (3.0) 34 (4.2) 19 (2.3) 1.29 (0.72–2.33) 1.82 (1.05–3.18) 0.71 (0.43–1.18)
Major or clinically relevant nonmajor 
bleeding
27 (3.2) 35 (4.3) 22 (2.7) 1.20 (0.69–2.10) 1.62 (0.96–2.73) 0.74 (0.46–1.22)
VTE, VTE-related death, myocardial infarc-
tion, stroke, cardiovascular disease–
related death, or major bleeding‡
20 (2.4) 20 (2.5) 86 (10.4) 0.23 (0.14–0.37) 0.24 (0.15–0.38) 0.97 (0.52–1.79)
* For patients who had more than one event, only the first event was considered. NA denotes not available.
† In the 2.5-mg apixaban group, 13 patients who were lost to follow-up were classified as having had a primary outcome event; in the 5-mg 
apixaban group, 20 patients who were lost to follow-up were classified as having had a primary outcome event; and in the placebo group,  
19 patients who were lost to follow-up were classified as having had a primary outcome event.
‡ A reduction in this composite outcome was considered to represent the net clinical benefit.
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of apixaban (a difference of −1.9 percentage 
points; 95% CI, −3.6 to −0.2). The difference in 
the rate of this outcome with the 2.5-mg dose as 
compared with the 5-mg dose was −1.2 percent-
age points (95% CI, −3.0 to 0.6).
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Figure 2. Kaplan–Meier Cumulative Event Rates.
Kaplan–Meier cumulative event rates are shown for the composite secondary efficacy outcome of symptomatic  
recurrent venous thromboembolism (VTE) or VTE-related death (Panel A) and for the secondary safety outcome of 
the composite of major or clinically relevant nonmajor bleeding (Panel B). The insets in both panels show the same 
data on an enlarged y axis.
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outcome of major bleeding or clinically relevant 
nonmajor bleeding are shown in Table 2. Figure 2B 
shows the time course of this composite outcome.
Other Outcomes
The composite outcome of symptomatic recur-
rent venous thromboembolism, death related to 
venous thromboembolism, myocardial infarction, 
stroke, death related to cardiovascular disease, 
or major bleeding occurred in 86 patients (10.4%) 
who were receiving placebo, as compared with 20 
patients (2.4%) who were receiving 2.5 mg of 
apixaban (a difference of 8.1 percentage points; 
95% CI, 5.8 to 10.4) and 20 patients (2.5%) who 
were receiving 5 mg of apixaban (a difference of 
7.9 percentage points; 95% CI, 5.6 to 10.2). The 
difference in the rate of this composite outcome 
with the 2.5-mg dose as compared with the 5-mg 
dose was −0.2 percentage points (95% CI, −1.7 to 
1.3). The rate of death from any cause was 1.7% 
in the placebo group, as compared with 0.8% and 
0.5% in the 2.5-mg and 5-mg apixaban groups, 
respectively.
The rates of adverse events were similar in 
the three study groups (Table S3 in the Supple-
mentary Appendix). Results of prespecified sub-
group analyses of the efficacy outcomes (Fig. 3, 
and Fig. S1 in the Supplementary Appendix) and 
the bleeding outcomes (Fig. S2 in the Supple-
mentary Appendix) were consistent with the 
observed overall treatment effects.
Follow-Up after the End of the Active Study 
Period
During the 30-day follow-up of the patients after 
the end of the active study period, symptomatic 
recurrent venous thromboembolism occurred in 
two patients (0.2%) who had received placebo, 
three patients (0.4%) who had received 2.5 mg of 
apixaban, and five patients (0.6%) who had re-
ceived 5 mg of apixaban. The composite outcome 
of myocardial infarction, stroke, or death related 
to cardiovascular disease occurred in two pa-
tients during the follow-up period: one who had 
received the lower dose of apixaban and one who 
had received the higher dose.
Discussion
This study showed that, as compared with pla-
cebo, both the 2.5-mg dose and the 5-mg dose of 
apixaban reduced the risk of recurrent venous 
thromboembolism (fatal or nonfatal). These ben-
efits were observed with rates of major bleeding 
that were low and similar to those in the placebo 
group.
The inclusion of a group that did not receive 
apixaban strengthens this study because it allows 
for an assessment of the efficacy and safety of 
the two doses of apixaban relative to the efficacy 
and safety of placebo. Although the inclusion of 
a placebo group could be criticized, patients who 
were enrolled in the trial had already received 
anticoagulation therapy for 6 to 12 months, and 
the entry criteria mandated clinical equipoise 
regarding the continuation or cessation of ther-
apy. Furthermore, patients who required contin-
ued anticoagulation, such as those with atrial 
fibrillation or the antiphospholipid syndrome, 
were excluded. Given that the proportion of pa-
tients with recurrent thromboembolism (fatal or 
nonfatal) in the placebo group was 8.8%, it is 
evident that these entry criteria identified pa-
tients with an appreciable risk of recurrence.
What are the implications of these findings? 
For patients with venous thromboembolism for 
whom there is uncertainty about the benefits and 
risks of continued therapy, the results of this 
study provide a rationale for continuing antico-
agulation therapy for an additional 12 months, 
because both the 2.5-mg twice-daily regimen of 
apixaban and the 5-mg twice-daily regimen were 
effective, safe, and simple to use. The number of 
patients who would need to be treated to prevent 
one episode of recurrent venous thromboembo-
lism (fatal or nonfatal) during the 1-year active 
study period was only 14, whereas the number 
needed for treatment to cause one episode of 
major or clinically relevant nonmajor bleeding 
was 200. It should be noted, however, that only 
15% of the patients in this study were older than 
75 years of age and few had a body weight below 
60 kg or moderate or severe renal impairment. 
Consequently, more data are needed to better 
determine the benefit-to-risk profile of apixaban 
with respect to bleeding in such patients.
Figure 3 (facing page). Relative Risk of the Composite 
Secondary Efficacy Outcome of Symptomatic Recurrent 
Venous Thromboembolism or Death Related to Venous 
Thromboembolism, According to Prespecified Subgroups.
DVT denotes deep-vein thrombosis, and PE pulmonary 
embolism.
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Additional studies will be needed to determine 
the potential net benefit and risk of extending 
treatment beyond 18 to 24 months. The reduc-
tion in arterial thrombotic events observed with 
apixaban raises the possibility that such events 
are part of the continuing risk of thrombosis in 
patients with venous thromboembolism.10,11
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